New AHA Statement Supports Single-Pill Combo Therapy for Hypertension

A recent scientific statement in the American Heart Association's journal Hypertension emphasizes the benefits of single-pill combination therapy for managing hypertension, which affects nearly half of U.S. adults. Combining two or more blood pressure medications in one pill can facilitate faster and more effective blood pressure reduction compared to multiple separate pills. This therapy aligns with the 2025 AHA/ACC guidelines recommending early treatment with combined medications for stage 2 hypertension patients (140/90 mm Hg or higher). The statement highlights the importance of single-pill combinations in improving patient adherence by simplifying medication regimens. However, less than half of treated patients currently achieve recommended blood pressure targets, partly due to challenges with multiple medications. Expanding available single-pill combinations, including triple and quadruple therapies, could enhance blood pressure control and reduce cardiovascular risks such as heart attack and stroke. Single-pill combinations differ from polypills, which additionally include statins or aspirin alongside blood pressure treatments for broader cardiovascular risk reduction. Despite the availability of about 200 medication combinations in the U.S., only a few are offered as single-pill options. Greater adoption of single-pill therapies could improve population health outcomes while also reducing healthcare costs related to cardiovascular events. The scientific statement was prepared by experts from the American Heart Association’s Councils on Hypertension, Cardiovascular and Stroke Nursing, and Clinical Cardiology. While informative about current evidence and clinical implementation strategies, the statement does not constitute formal treatment guidelines. It identifies knowledge gaps for further research to optimize hypertension management through combination therapies. Overall, the statement reinforces the value of medication simplification strategies within hypertension treatment protocols, aiming to improve patient compliance and clinical outcomes. This development is of particular relevance to healthcare providers, payers, and stakeholders focused on cardiovascular risk management and cost-efficient care delivery in the U.S. market.